Dr. Nigel Key and Dr. Anna Falanga join us for a conversation on the updated ASCO VTE prophylaxis and treatment in patients with cancer guideline. They discuss recent evidence assessing apixaban for ...

Thromboembol in blood vessel. Clot formation, 3D illustration Researchers sought to compare oral apixaban and subcutaneous dalteparin for treating patients with cancer-related venous thromboembolism.

This multicenter retrospective cohort study included adult patients with cancer diagnosed with venous thromboembolism (VTE) hospitalized in Thailand from 2017 to 2021. Anticoagulants were classified ...

A descriptive, qualitative study investigated the experiences and perspectives of patients with venous thromboembolism on shared decision-making and treatment with anticoagulants. Patients who have ...

The main goal of DVT treatment is to stop a blood clot from breaking loose and traveling to the lungs, a condition called pulmonary embolism (PE). This can block blood flow to the lungs and cause ...

Venous thromboembolism (VTE) is serious condition that begins with a blood clot in a vein – often in the lower leg – that makes its way to the lungs, causing a pulmonary embolism with potentially ...

Anybody can develop a deep vein thrombosis (DVT). It's a serious public health issue. But some are more likely to get this clot – or even die from it – than others due to differences in treatment.

A model incorporating C-reactive protein and D-Dimer may be prognostic for bladder cancer-related thrombosis. Combining C-reactive protein (CRP) and D-dimer (D-D) levels may improve prediction of ...

Patients with active cancer who developed a blood clot, or venous thromboembolism (VTE), and were treated with blood-thinning medication for at least six months, followed by an additional 12 months of ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...